Xantos Biomedicine and QIAGEN Announce
Aug 08 2005

Xantos Biomedicine and QIAGEN Announce

Munich, Germany, and Venlo, The Netherlands, August 8, 2005: Xantos Biomedicine AG, a functional biology and drug discovery company and QIAGEN N.V. (Nasdaq: QGEN; Deutsche Börse: QIA, Prime Standard), the world's leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids and proteins announced today their partnership for co-marketing QIAGEN's proprietary TOM-amidite chemistry based genome-wide RNAi products with Xantos' automated cell-based screening platform, XantoScreenTM. By combining the capabilities of both companies' platforms customers will be able to rapidly perform gene analysis and unravel the function and role of genes that are relevant to their area of interest.

 

Xantos provides XantoScreenTM for the discovery and functional validation of novel targets on a genome-wide basis. The system enables high throughput and automated cDNA transfection studies (over expression of genes) or RNAi (gene silencing) to be carried out rapidly. This powerful system can be customized to a range of high content cellular screening assays and enables individual cDNAs, RNAi molecules or proteins to be studied in combination with or without inhibitory molecules, to identify and validate targets, ligands, receptors, compounds or pathways.

 

QIAGEN is a leading supplier of high performance validated siRNA libraries and holds a leading position in high throughput siRNA synthesis technology. It employs its patented TOM-amidites chemistry to produce High Performance Purity (HPP) grade siRNA for efficient gene silencing. As a licensed supplier of siRNA, QIAGEN offers pre-designed, genome-wide siRNA molecules. QIAGEN's siRNA products combined with its RNA transfection, purification and detection technologies provide a fully integrated solution for ultra high-throughput gene silencing.

 

"We are delighted to form an alliance with QIAGEN", said Stephan Wehselau, Xantos' Chief Executive Officer. "By joining forces with the market leader in siRNA based gene silencing we will significantly expand our customer base. Our customers will now be able to benefit from two technology platforms for functional gene analysis: the use of cDNA collections and QIAGEN's siRNA reagents for gene silencing experiments."

 

"Xantos genome-wide cellular screening assay is a perfect match to QIAGEN's Human Druggable Genome siRNA Set, and Human Whole Genome siRNA Set", said Jie Kang, QIAGEN's Vice President Research & Development. "The option to study gene expression related phenomena from two angles provides the ability to gain unique new insights and help expand this rapidly growing field of research."

 

About QIAGEN

 

QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany, the United States, Japan, the United Kingdom, Switzerland, France, Italy, Australia, Norway, Austria, Canada, Sweden, and the Netherlands believes it is the world's leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids and proteins. QIAGEN has developed a comprehensive portfolio of more than 320 proprietary, consumable products for nucleic acid and protein separation, purification and handling, nucleic acid amplification, as well as automated instrumentation, synthetic nucleic acid products and related services. QIAGEN's products are sold in more than 42 countries throughout the world to academic research markets and to leading pharmaceutical and biotechnology companies. In addition, QIAGEN is positioning its products for sale into developing commercial markets, including applied testing markets, clinical research, nucleic acid-based molecular diagnostics, and genetic vaccination and gene therapy. QIAGEN employs more than 1,500 people worldwide. Further information on QIAGEN can be found at http://www.qiagen.com/.

 

About Xantos Biomedicine AG

 

Xantos Biomedicine AG is a functional biology and drug discovery company that is focusing on the identification and validation of disease relevant human genes. Studies on biological functions are carried out rapidly by screening for phenotypic changes caused by increase of gene function in mammalian cell systems. For this Xantos has established the proprietary high-throughput, fully automated cellular gene-transfection and assay system XantoScreen TM that is used for several functional applications, including molecular drug profiling, target / pathway profiling, target and protein identification as well as lead identification. XantoScreenTM enables the fully automated and standardized functional analysis of 100,000 to 300,000 genes per month in cell systems. Xantos has one of the world's largest full-length human cDNA collections (35,000 clones), several high quality cDNA libraries from various human tissues and several cell systems available for high throughput analysis. The Company uses its technology for its own discovery programs in cancer and metabolic diseases. Xantos focuses on the development of therapeutics based on secreted proteins involved in angiogenesis of cancer cells, in differentiation of fat cells and in the induction of insulin resistance. Xantos has already identified several disease relevant new targets and proteins and is searching for collaboration partners. Xantos is offering its technology, the human cDNA collections, libraries and functional cell assay systems on a fee-for-service basis for technology-driven interactions. Further information on Xantos Biomedicine can be found under http://www.xantos.de/.

Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the applied testing markets, clinical research markets and proteomics markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's, products ( including fluctuations due to the level and timing of customers' funding, budgets, and other factors ), difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors' products, market acceptance of QIAGEN's new products and the integration of acquisitions of technologies and businesses. For further information, refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).

###

 

Contacts:

IR QIAGEN N.V.

Phone: +49 2103 29 11710

Fax: +49 2103 29 21710

Email: ir@qiagen.com

 

FOLLOW US ON SOCIAL MEDIA

Share this page